A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERα protein

Carcinogenesis

Volumn 33, Issue 5, 2012, Pages 1089-1097

  Tiong, Chi Tze ^a   Chen, Chen ^a   Zhang, Shi Jun ^a   Li, Jun ^a   Soshilov, Anatoly ^b   Denison, Michael S ^b   Lee, Lawrence Soon U ^c   Tam, Vincent H ^c,d   Wong, Shih Peng ^a   Xu, H Eric ^e   Yong, Eu Leong ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Dept Medicine Endocrinol Diabet   (Singapore)

^d UNIVERSITY OF HOUSTON   (United States)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FLAVONE DERIVATIVE; GENISTEIN; ICARITIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84860487512     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs110     Document Type: Article

References (49)

1. Wolff, A.C. et al. (2011) Estrogen receptor: a never ending story? J. Clin. Oncol., 29, 2955-2958.
2. Yager, J.D. et al. (2006) Estrogen carcinogenesis in breast cancer. N. Engl. J. Med., 354, 270-282.
3. Welboren, W.J. et al. (2009) Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr. Relat. Cancer, 16, 1073-1089.
4. Hammond, M.E. et al. (2011) Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J. Clin. Oncol., 29, e458.
5. Burstein, H.J. et al. (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol., 28, 3784-3796.
6. Early Breast Cancer Trialists' Collaborative Group. (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378, 771-784.
7. Wu, A.H. et al. (2008) Soy intake and breast cancer risk in Singapore Chinese Health Study. Br. J. Cancer, 99, 196-200.
8. Iwasaki, M. et al. (2008) Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J. Clin. Oncol., 26, 1677-1683.
9. Shu, X.O. et al. (2009) Soy food intake and breast cancer survival. JAMA, 302, 2437-2443.
10. Lindahl, G. et al. (2011) Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer. Cancer Res., 71, 51-60.
11. Liu, B. et al. (2005) Low-dose dietary phytoestrogen abrogates tamoxifenassociated mammary tumor prevention. Cancer Res., 65, 879-886.
12. Milligan, S.R. et al. (1999) Identification of a potent phytoestrogen in hops (Humulus lupulus L.) and beer. J. Clin. Endocrinol. Metab., 84, 2249-2252.
13. Overk, C.R. et al. (2005) Comparison of the in vitro estrogenic activities of compounds from hops (Humulus lupulus) and red clover (Trifolium pratense). J. Agric. Food Chem., 53, 6246-6253.
14. Khan, N. et al. (2008) A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res., 68, 8555-8563.
15. Wu, H. et al. (2003) Chemical and pharmacological investigations of Epimedium species: a survey. Prog. Drug Res., 60, 1-57.
16. Wong, S.P. et al. (2009) Pharmacokinetics of prenylflavonoids and correlations with the dynamics of estrogen action in sera following ingestion of a standardized Epimedium extract. J. Pharm. Biomed. Anal., 50, 216-223.
17. He, J. et al. (2010) Icaritin induces apoptosis of HepG2 cells via the JNK1 signaling pathway independent of the estrogen receptor. Planta Med., 76, 1834-1839.
18. Wang, Y. et al. (2010) Icariin exterts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. Eur. J. Pharmacol., 635, 40-48.
19. Huang, J. et al. (2007) Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sci., 81, 832-840.
20. Tong, J.S. et al. (2011) Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells. PLoS One, 6, e16781.
21. Guo, Y. et al. (2011) An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur. J. Pharmacol., 658, 114-122.
22. Ye, H.Y. et al. (2005) Estrogenic effects of two derivatives of icariin on human breast cancer MCF-7 cells. Phytomedicine, 12, 735-741.
23. Wong, S.P. et al. (2007) Ultrasensitive cell-based bioassay for the measurement of global estrogenic activity of flavonoid mixtures revealing additive, restrictive, and enhanced actions in binary and higher order combinations. Assay Drug Dev. Technol., 5, 355-362.
24. Denison, M.S. et al. (2002) Analysis of the Aryl Hydrocarbon Receptor (AhR) Signal Transduction Pathway. Curr. Protoc. Toxicol., 11, 4.8.1-4.8.45.
25. Grandien, K. et al. (1995) Estrogen target tissue determines alternative promoter utilization of the human estrogen receptor gene in osteoblasts and tumor cell lines. Endocrinology, 136, 2223-2229.
26. Rae, J.M. et al. (2005) GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res. Treat., 92, 141-149.
27. Abdelrahim, M. et al. (2006) 3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha. Cancer Res., 66, 2459-2467.
28. Swedenborg, E. et al. (2010) AhR and ARNT modulate ER signaling. Toxicology, 268, 132-138.
29. Wormke, M. et al. (2003) The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol. Cell. Biol., 23, 1843-1855.
30. Ohtake, F. et al. (2007) Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature, 446, 562-566.
31. Bock, K.W. (1994) Aryl hydrocarbon or dioxin receptor: biologic and toxic responses. Rev. Physiol. Biochem. Pharmacol., 125, 1-42.
32. Ohtake, F. et al. (2009) AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochem. Pharmacol., 77, 474-484.
33. Shen, P. et al. (2007) Taxonomic, genetic, chemical and estrogenic characteristics of Epimedium species. Phytochemistry, 68, 1448-1458.
34. Tateishi, Y. et al. (2004) Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J., 23, 4813-4823.
35. Shao, W. et al. (2004) Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc. Natl Acad. Sci. USA, 101, 11599-11604.
36. Henrich, L.M. et al. (2003) Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction. Mol. Cell. Biol., 23, 5979-5988.
37. Chu, I. et al. (2007) Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J. Clin. Invest., 117, 2205-2215.
38. Zhang, H. et al. (2006) The catalytic subunit of the proteasome is engaged in the entire process of estrogen receptor-regulated transcription. EMBO J., 25, 4223-4233.
39. Hall, J.M. et al. (2010) Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol. Endocrinol., 24, 359-369.
40. Baba, T. et al. (2005) Intrinsic function of the aryl hydrocarbon (dioxin) receptor as a key factor in female reproduction. Mol. Cell. Biol., 25, 10040-10051.
41. Hushka, L.J. et al. (1998) Characterization of 2,3,7,8-tetrachlorodibenzofuran-dependent suppression and AH receptor pathway gene expression in the developing mouse mammary gland. Toxicol. Appl. Pharmacol., 152, 200-210.
42. Oenga, G.N. et al. (2004) TCDD and PCBs inhibit breast cancer cell proliferation in vitro. Toxicol. In Vitro, 18, 811-819.
43. Elferink, C.J. (2003) Aryl hydrocarbon receptor-mediated cell cycle control. Prog. Cell Cycle Res., 5, 261-267.
44. Puga, A. et al. (2002) Role of the aryl hydrocarbon receptor in cell cycle regulation. Chem. Biol. Interact., 141, 117-130.
45. Kawajiri, K. et al. (2009) Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+} mice with natural ligands. Proc. Natl Acad. Sci. USA, 106, 13481-13486.
46. Gierthy, J.F. et al. (1993) Correlation of in vitro and in vivo growth suppression of MCF-7 human breast cancer by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res., 53, 3149-3153.
47. McGregor, D.B. et al. (1998) An IARC evaluation of polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans as risk factors in human carcinogenesis. Environ. Health Perspect., 106 (suppl. 2), 755-760.
48. Chen, J.R. et al. (2005) Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens. J. Biol. Chem., 280, 4632-4638.
49. Xie, H. et al. (2011) Estrogen receptor alpha36 mediates a bone-sparing effect of 17beta-estrodiol in postmenopausal women. J. Bone Miner. Res., 26, 156-168.